Boston Scientific lands cardiac patent win over Medtronic

September 18, 2012 by MassDevice staff

A Federal Circuit Court overturns a Medtronic win, sending the case back to a lower court to determine whether Medtronic's cardiac rhythm therapy devices infringe on Boston Scientific's exclusively licensed patents.

legal gavel

Medical device giants Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) will head back to court to hash out the details of a years-long patent battle over cardiac rhythm therapy device technology.

U.S. Court of Appeals for the Federal Circuit Judges this week overturned a Delaware court's decision that Medtronic hadn't infringed on Boston Scientific's patents, finding that the lower court used "a legally incorrect allocation of the burden of proof." The federal court sent the case back for reconsideration.

The long-running dispute concerns fundamental CRT technology covered in a pair of patents issued to CRM pioneer Dr. Morton Mower, credited with inventing the technology that ultimately became known as a cardiac resynchronization therapy device.

Sign up to get our free newsletters delivered right to your inbox.

Mower's CRT helps the hearts left and right ventricles beat simultaneously, increasing the heart's efficiency, and 2 patents for the device are the property of Mirowski Family Ventures, which exclusively licenses both to Guidant Corp. Boston Scientific acquired Guidant in 2006 for an eyebrow-raising $26 billion.